Search | Page 4 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. MDS/AML patients benefit from novel study

    ... 109 patients with AML and MDS undergoing treatment with azacitidine (AZA) and vorinostat. Research results were presented Dec. 3 at ...

    Article last updated 12/08/2016 - 2:34pm.

  2. Expression of nucleoside metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine

    ... The nucleoside analog azacitidine (AZA) is used in the treatment of myelodysplastic syndromes ...

    Research Article last updated 11/14/2013 - 11:22am.

  3. Effectiveness of azacitidine in higher-risk myelodysplastic syndromes

    ...

    Research Article last updated 06/23/2016 - 9:31am.

  4. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia

    ... and clinical activity of an oral formulation of azacitidine in patients with myelodysplastic syndromes (MDSs), ... AND METHODS: Patients received 1 cycle of subcutaneous (SC) azacitidine (75 mg/m2) on the first 7 days of cycle 1, followed by oral ...

    Research Article last updated 10/11/2011 - 5:58pm.

  5. Top expert calls future MDS/AML care “promising”

    ... agents, such as SGI-110 (guadecitabine) or CC-486 (oral azacitidine ). What are the ongoing clinical trials in this space? ...

    Article last updated 11/02/2016 - 11:28am.

  6. CASCADE (SGN33A-005)

    ... talirine (SGN-CD33A; 33A) combined with either azacitidine or decitabine extends overall survival longer than placebo combined with either azacitidine or decitabine. Status:  ...

    Clinical Trial last updated 06/19/2017 - 2:43pm.

  7. Azacitidine in lower-risk myelodysplastic syndromes.

    ... 1, 2009 Azacitidine is the first agent to significantly prolong overall survival ... (MDS). Here, we review currently available data on azacitidine treatment in lower-risk MDS. In a phase III study, a subset of ...

    Research Article last updated 10/11/2011 - 5:58pm.

  8. Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes.

    ... Lenalidomide and azacitidine are active in MDS patients, and may complement each other by ... . A recent Phase I trial testing the lenalidomide and azacitidine combination yielded encouraging results; however, lenalidomide’s ...

    Research Article last updated 10/11/2011 - 5:58pm.

  9. Azacitidine in the management of patients with myelodysplastic syndromes.

    ... of irreversible DNA methlytransferase inhibitors such as azacitidine was investigated with promising outcomes in the treatment of MDS. Azacitidine was initially approved in the USA by the Food and Drug ... in the AZA-001 study of patients with higher-risk MDS. Azacitidine has demonstrated significant and clinically meaningful prolongation ...

    Research Article last updated 05/14/2013 - 2:48pm.

  10. Current State of the Art: Management of Higher Risk Myelodysplastic Syndromes

    ... that alter the natural history of the disease. Azacitidine is the only drug reported to improve overall survival in higher ...

    Research Article last updated 09/19/2016 - 11:11am.